NCT02243436 2019-04-24Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaPhase 1/2 Completed67 enrolled